1 / 5

Nasal Drug Delivery Market

Many drugs cannot penetrate the blood-brain barrier to the extent that they can treat Central Nervous System (CNS) disorders. Most medicines and solutes cannot cross through the endothelial cells of blood capillaries supplying the brain because of tight junctions. Due to the intersections between the cells, capillary walls do not flow in bulk like other tissue. Nasal delivery or nasal spray is one approach to delivering drugs. There are significant differences in the nasal anatomy and physiology of different animal species and humans. It makes it very difficult to establish a direct correlatio

25438
Télécharger la présentation

Nasal Drug Delivery Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nasal drug delivery Market

  2. Effective drug delivery techniques via the nose. The The vestibule is a part of the nose that is not very vascular and the permeability of the drug through this region is not remarkable The respiratory region allows moderate to the high permeability of drugs as the vascularization in this part is supportive for drug delivery. olfactory region is highly vascular which results in high permeability.

  3. The type of medicine to be delivered through the nasal cavity is segregated into powder, liquid, spray and semisolid formulations.

  4. Anti-CD3: Nasal Treatment Biotechnology company Titiana Life Sciences plans to advance Foralumab. 1 It is an anti-CD3 human monoclonal antibody-based on Covid-19 research. 2 In a recent clinical study, nasally administered anti-CD3 monoclonal antibodies reduced pulmonary and systemic inflammation in mild to moderate patients. 3

  5. GLOBAL MARKET DATABASE Read the full blog at www.globalmarketdatabase.com demo@globalmarketdatabase.com

More Related